Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: Bispecifics poised to enter new era
Decade after first approval, bispecifics on the precipice of going mainstream
BioCentury | Dec 20, 2024
Editor's Commentary
Don’t sleep on China’s academic innovation: a Perspective
Forget the ‘fast follower’ narrative: Plenty of new target biology is now coming from Chinese university labs
BioCentury | Jun 6, 2024
Product Development
Solid tumor immunotherapies headline ASCO’s first-in-human studies
A focus on first-in-class innovation and solid tumor applications
BioCentury | Jan 8, 2024
Deals
Merck acquisition brings back hope for Harpoon’s trispecific technology
Merck will acquire Harpoon and its DLL3 trispecific for $680M
BioCentury | Oct 5, 2023
Regulation
Oct. 4 Quick Takes: FDA’s ODAC backs US WorldMeds’ eflornithine for neuroblastoma
Plus: ClavystBio launches space for start-ups in Singapore and updates from Novavax, Iambic, Sandoz, Shorla and more
BioCentury | Jun 8, 2023
Discovery & Translation
Modalities, not targets, drive translational innovation at ASCO23
BioCentury’s analysis of first-in-human studies at ASCO 2023
BioCentury | May 3, 2023
Distillery Therapeutics
Blocking PYGO2 to overcome immunotherapy resistance in prostate cancer
BioCentury | Sep 9, 2022
Product Development
China driving solid tumor CAR T innovation
Chinese investigator-initiated trials are accelerating CAR T innovation, bringing solid tumor advances to ESMO22
BioCentury | May 24, 2022
Distillery Therapeutics
An EpCAM- and CD133-expressing cell population for biliary disease
BioCentury | Mar 25, 2022
Discovery & Translation
AACR22 tackles the CAR T solid tumor challenge
Dual-targeting CARs, new targets and bispecific adaptors among the top innovations
Items per page:
1 - 10 of 117